Burmester, Gerd R https://orcid.org/0000-0001-7518-1131
Strand, Vibeke
Rubbert-Roth, Andrea
Amital, Howard
Raskina, Tatiana
Gómez-Centeno, Antonio
Pena-Rossi, Claudia
Gervitz, Leon
Thangavelu, Karthinathan
St John, Gregory
Boklage, Susan
Genovese, Mark C https://orcid.org/0000-0001-5294-4503
Clinical trials referenced in this document:
Documents that mention this clinical trial
FRI0108 ASSOCIATION BETWEEN CHANGES IN C-REACTIVE PROTEIN AT WEEK 12 AND PATIENT-REPORTED OUTCOMES AT WEEK 24 WITH SARILUMAB THERAPY ACROSS THREE PIVOTAL PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2020-eular.2181
THU0167 ASSOCIATIONS BETWEEN RHEUMATOID ARTHRITIS DISEASE ACTIVITY AND PATIENT-REPORTED OUTCOMES IN SARILUMAB CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2020-eular.1977
SAT0125 LONG-TERM SAFETY WITH SARILUMAB PLUS CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND SARILUMAB MONOTHERAPY IN RHEUMATOID ARTHRITIS: AN INTEGRATED ANALYSIS WITH 9,000 PATIENT-YEARS OF FOLLOW-UP
https://doi.org/10.1136/annrheumdis-2019-eular.245
FRI0240 Rheumatoid arthritis (RA) impact following treatment with sarilumab: patient reported outcomes using the raid scale from two randomized phase III trials
https://doi.org/10.1136/annrheumdis-2017-eular.3448
SAT0137 PATIENTS (PTS) SWITCHED TO SARILUMAB FROM ADALIMUMAB ACHIEVE CLINICALLY IMPORTANT IMPROVEMENTS IN RA DISEASE ACTIVITY: RESULTS FROM MONARCH TRIAL OPEN-LABEL EXTENSION (OLE)
https://doi.org/10.1136/annrheumdis-2019-eular.4646
SAT0183 Switching from adalimumab to sarilumab is associated with comparable efficacy but lower functional improvement versus continuous sarilumab monotherapy through 48-week open-label extension (OLE) of the phase 3 monarch trial
https://doi.org/10.1136/annrheumdis-2018-eular.1372
SAT0102 NONINFLAMMATORY PAIN IS A FREQUENT PHENOMENON IN RHEUMATOID ARTHRITIS AND RESPONDS WELL TO TREATMENT WITH SARILUMAB
https://doi.org/10.1136/annrheumdis-2020-eular.2015
Deciphering differential biomarkers for anti-interleukin-6 receptor and anti-tumour necrosis factor-α treatment response in rheumatoid arthritis by multiomics analysis
https://doi.org/10.1136/rmdopen-2025-005556
SAT0180 Efficacy and safety of sarilumab 200 MG Q2W administered as combination therapy or monotherapy in different patient populations with active RA
https://doi.org/10.1136/annrheumdis-2017-eular.1275
FRI0227 Sarilumab significantly suppresses circulating biomarkers of bone resorption and cardiovascular risk compared with adalimumab: biomarker analysis from the phase 3 monarch study
https://doi.org/10.1136/annrheumdis-2017-eular.4534
SAT0121 EFFECT OF SARILUMAB ON GLYCOSYLATED HEMOGLOBIN IN PATIENTS WITH RHEUMATOID ARTHRITIS AND DIABETES
https://doi.org/10.1136/annrheumdis-2019-eular.3259
THU0223 Impact of treatment in patients with rheumatoid arthritis and depressive symptoms in the monarch phase 3 trial of sarilumab
https://doi.org/10.1136/annrheumdis-2018-eular.3714
Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension
https://doi.org/10.1136/rmdopen-2019-001017
Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial
https://doi.org/10.1136/annrheumdis-2016-210310
OP0102 Patient reported benefits of sarilumab monotherapy versus adalimumab monotherapy in adult patients with active rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2017-eular.2955
THU0162 LIKELIHOOD OF CLINICAL WORSENING AMONG RHEUMATOID ARTHRITIS PATIENTS WHO ACHIEVED A PARTIAL RESPONSE TO ADALIMUMAB AND WERE SUBSEQUENTLY SWITCHED TO SARILUMAB
https://doi.org/10.1136/annrheumdis-2020-eular.1729
SAT0202 Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy in patients with active rheumatoid arthritis in the phase 3 monarch study, including subpopulations
https://doi.org/10.1136/annrheumdis-2017-eular.4540
Documents that mention this clinical trial
FRI0108 ASSOCIATION BETWEEN CHANGES IN C-REACTIVE PROTEIN AT WEEK 12 AND PATIENT-REPORTED OUTCOMES AT WEEK 24 WITH SARILUMAB THERAPY ACROSS THREE PIVOTAL PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2020-eular.2181
THU0167 ASSOCIATIONS BETWEEN RHEUMATOID ARTHRITIS DISEASE ACTIVITY AND PATIENT-REPORTED OUTCOMES IN SARILUMAB CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2020-eular.1977
SAT0125 LONG-TERM SAFETY WITH SARILUMAB PLUS CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND SARILUMAB MONOTHERAPY IN RHEUMATOID ARTHRITIS: AN INTEGRATED ANALYSIS WITH 9,000 PATIENT-YEARS OF FOLLOW-UP
https://doi.org/10.1136/annrheumdis-2019-eular.245
FRI0240 Rheumatoid arthritis (RA) impact following treatment with sarilumab: patient reported outcomes using the raid scale from two randomized phase III trials
https://doi.org/10.1136/annrheumdis-2017-eular.3448
SAT0137 PATIENTS (PTS) SWITCHED TO SARILUMAB FROM ADALIMUMAB ACHIEVE CLINICALLY IMPORTANT IMPROVEMENTS IN RA DISEASE ACTIVITY: RESULTS FROM MONARCH TRIAL OPEN-LABEL EXTENSION (OLE)
https://doi.org/10.1136/annrheumdis-2019-eular.4646
SAT0183 Switching from adalimumab to sarilumab is associated with comparable efficacy but lower functional improvement versus continuous sarilumab monotherapy through 48-week open-label extension (OLE) of the phase 3 monarch trial
https://doi.org/10.1136/annrheumdis-2018-eular.1372
SAT0102 NONINFLAMMATORY PAIN IS A FREQUENT PHENOMENON IN RHEUMATOID ARTHRITIS AND RESPONDS WELL TO TREATMENT WITH SARILUMAB
https://doi.org/10.1136/annrheumdis-2020-eular.2015
Deciphering differential biomarkers for anti-interleukin-6 receptor and anti-tumour necrosis factor-α treatment response in rheumatoid arthritis by multiomics analysis
https://doi.org/10.1136/rmdopen-2025-005556
SAT0180 Efficacy and safety of sarilumab 200 MG Q2W administered as combination therapy or monotherapy in different patient populations with active RA
https://doi.org/10.1136/annrheumdis-2017-eular.1275
FRI0227 Sarilumab significantly suppresses circulating biomarkers of bone resorption and cardiovascular risk compared with adalimumab: biomarker analysis from the phase 3 monarch study
https://doi.org/10.1136/annrheumdis-2017-eular.4534
SAT0121 EFFECT OF SARILUMAB ON GLYCOSYLATED HEMOGLOBIN IN PATIENTS WITH RHEUMATOID ARTHRITIS AND DIABETES
https://doi.org/10.1136/annrheumdis-2019-eular.3259
THU0223 Impact of treatment in patients with rheumatoid arthritis and depressive symptoms in the monarch phase 3 trial of sarilumab
https://doi.org/10.1136/annrheumdis-2018-eular.3714
Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension
https://doi.org/10.1136/rmdopen-2019-001017
Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial
https://doi.org/10.1136/annrheumdis-2016-210310
OP0102 Patient reported benefits of sarilumab monotherapy versus adalimumab monotherapy in adult patients with active rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2017-eular.2955
THU0162 LIKELIHOOD OF CLINICAL WORSENING AMONG RHEUMATOID ARTHRITIS PATIENTS WHO ACHIEVED A PARTIAL RESPONSE TO ADALIMUMAB AND WERE SUBSEQUENTLY SWITCHED TO SARILUMAB
https://doi.org/10.1136/annrheumdis-2020-eular.1729
SAT0202 Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy in patients with active rheumatoid arthritis in the phase 3 monarch study, including subpopulations
https://doi.org/10.1136/annrheumdis-2017-eular.4540
Documents that mention this clinical trial
FRI0108 ASSOCIATION BETWEEN CHANGES IN C-REACTIVE PROTEIN AT WEEK 12 AND PATIENT-REPORTED OUTCOMES AT WEEK 24 WITH SARILUMAB THERAPY ACROSS THREE PIVOTAL PHASE 3 STUDIES
https://doi.org/10.1136/annrheumdis-2020-eular.2181
THU0167 ASSOCIATIONS BETWEEN RHEUMATOID ARTHRITIS DISEASE ACTIVITY AND PATIENT-REPORTED OUTCOMES IN SARILUMAB CLINICAL TRIALS
https://doi.org/10.1136/annrheumdis-2020-eular.1977
SAT0125 LONG-TERM SAFETY WITH SARILUMAB PLUS CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND SARILUMAB MONOTHERAPY IN RHEUMATOID ARTHRITIS: AN INTEGRATED ANALYSIS WITH 9,000 PATIENT-YEARS OF FOLLOW-UP
https://doi.org/10.1136/annrheumdis-2019-eular.245
FRI0240 Rheumatoid arthritis (RA) impact following treatment with sarilumab: patient reported outcomes using the raid scale from two randomized phase III trials
https://doi.org/10.1136/annrheumdis-2017-eular.3448
SAT0137 PATIENTS (PTS) SWITCHED TO SARILUMAB FROM ADALIMUMAB ACHIEVE CLINICALLY IMPORTANT IMPROVEMENTS IN RA DISEASE ACTIVITY: RESULTS FROM MONARCH TRIAL OPEN-LABEL EXTENSION (OLE)
https://doi.org/10.1136/annrheumdis-2019-eular.4646
SAT0183 Switching from adalimumab to sarilumab is associated with comparable efficacy but lower functional improvement versus continuous sarilumab monotherapy through 48-week open-label extension (OLE) of the phase 3 monarch trial
https://doi.org/10.1136/annrheumdis-2018-eular.1372
SAT0102 NONINFLAMMATORY PAIN IS A FREQUENT PHENOMENON IN RHEUMATOID ARTHRITIS AND RESPONDS WELL TO TREATMENT WITH SARILUMAB
https://doi.org/10.1136/annrheumdis-2020-eular.2015
Deciphering differential biomarkers for anti-interleukin-6 receptor and anti-tumour necrosis factor-α treatment response in rheumatoid arthritis by multiomics analysis
https://doi.org/10.1136/rmdopen-2025-005556
SAT0180 Efficacy and safety of sarilumab 200 MG Q2W administered as combination therapy or monotherapy in different patient populations with active RA
https://doi.org/10.1136/annrheumdis-2017-eular.1275
FRI0227 Sarilumab significantly suppresses circulating biomarkers of bone resorption and cardiovascular risk compared with adalimumab: biomarker analysis from the phase 3 monarch study
https://doi.org/10.1136/annrheumdis-2017-eular.4534
SAT0121 EFFECT OF SARILUMAB ON GLYCOSYLATED HEMOGLOBIN IN PATIENTS WITH RHEUMATOID ARTHRITIS AND DIABETES
https://doi.org/10.1136/annrheumdis-2019-eular.3259
THU0223 Impact of treatment in patients with rheumatoid arthritis and depressive symptoms in the monarch phase 3 trial of sarilumab
https://doi.org/10.1136/annrheumdis-2018-eular.3714
Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension
https://doi.org/10.1136/rmdopen-2019-001017
Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial
https://doi.org/10.1136/annrheumdis-2016-210310
OP0102 Patient reported benefits of sarilumab monotherapy versus adalimumab monotherapy in adult patients with active rheumatoid arthritis
https://doi.org/10.1136/annrheumdis-2017-eular.2955
THU0162 LIKELIHOOD OF CLINICAL WORSENING AMONG RHEUMATOID ARTHRITIS PATIENTS WHO ACHIEVED A PARTIAL RESPONSE TO ADALIMUMAB AND WERE SUBSEQUENTLY SWITCHED TO SARILUMAB
https://doi.org/10.1136/annrheumdis-2020-eular.1729
SAT0202 Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy in patients with active rheumatoid arthritis in the phase 3 monarch study, including subpopulations
https://doi.org/10.1136/annrheumdis-2017-eular.4540
Funding for this research was provided by:
Regeneron Pharmaceuticals
Sanofi Genzyme